| answer text |
<p>The Medicines and Healthcare products Regulatory Agency has assessed the capacity
that will be required in both a deal and a ‘no deal’ European Union exit scenario.
This is based on scrutiny of resource and careful assessment of the Agency’s ability
to support the pharmaceutical and medical device industries.</p><p>Any gaps in resource
have been identified by the agency, and sufficiently addressed. In the case of a ‘no
deal’ scenario, the Agency has developed and is prepared to implement a new IT system
that will sufficiently support industry to continue to operate in a smooth transition.
The Agency continues to engage industry to ensure any concerns are addressed and that
appropriate transparency is maintained.</p>
|
 |
